Washington Accelerates the Psychedelic Revolution. Three Winners!
Reading Time: 4 minutes
The Executive Order signed on April 18, 2026, to accelerate medical treatments for severe mental illnesses marks a fundamental turning point for the psychedelic medicine sector. This term describes an innovative class of therapies that utilize psychoactive substances to stimulate the brain to "rewire." The White House has explicitly directed the authorities (FDA, DEA) to reduce bureaucratic hurdles for substances that promise significant breakthroughs in treatment-resistant depression (TRD). For AtaiBeckley (i) (WKN A41WEP, ticker: ATAI), this...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
